Lumosa's LT3001 Shows Promise for Disabling Acute Ischemic Stroke

Phase 2 trials demonstrate functional improvements in patients ineligible for standard stroke treatments

Published on Feb. 9, 2026

Got story updates? Submit your updates here. ›

Lumosa Therapeutics announced positive results from two independent Phase 2 clinical trials of its novel stroke drug LT3001. The data revealed that LT3001 delivers meaningful functional improvements in patients suffering from disabling acute ischemic stroke (AIS), offering new hope for those who cannot receive standard reperfusion treatments. The trials showed LT3001's potential to transform outcomes for stroke patients facing limited therapeutic options, with particularly impressive results in moderate stroke patients with disabling symptoms.

Why it matters

Acute ischemic stroke affects millions globally, with many patients experiencing disabling symptoms that severely impact their quality of life and independence. Current reperfusion therapies are not suitable for all patients, so LT3001's unique dual mechanism - enhancing the body's natural clot-dissolving processes while protecting brain tissue from oxidative damage - offers a new therapeutic pathway for these underserved patients.

The details

The LT3001-202 trial conducted in China showed that moderate stroke patients with disabling symptoms treated with LT3001 achieved 8% and 13% improvements in modified Rankin Scale (mRS) scores of 0-1 and 0-2 respectively, compared to placebo. LT3001 also showed improvement in functional outcomes in LAA and mismatch-positive populations. The complementary LT3001-205 trial, spanning the US, EU, and Taiwan, reinforced LT3001's efficacy signals, with patients showing disabling features achieving mRS 0-1 outcomes more often with LT3001 (27%) compared to placebo (17%).

  • The LT3001-202 trial was conducted in China.
  • The LT3001-205 trial spanned the US, EU, and Taiwan.

The players

Lumosa Therapeutics

A clinical-stage pharmaceutical company dedicated to the development of novel therapies and solutions for neurologic diseases with urgent unmet medical need.

Thomas Devlin, MD, PhD, FSVIN

Director of the CHI Memorial Neuroscience Institute, Professor of Neurology Morehouse School of Medicine and principal investigator of the LT3001-205 study.

Sheng-Wen Yeh (Mimi) Ph.D.

General manager of Lumosa Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“Across the two Phase 2 trials, LT3001 demonstrated a favorable safety profile, with no increase in symptomatic intracranial hemorrhage (sICH) despite multi-dose administration over 3 days. LT3001 showed potential benefit beyond the conventional thrombolytic time window, supporting its use in patients ineligible for IV thrombolysis or EVT, a population with high unmet need. The consistency of results across two independent trials, using different selection strategies, strengthens our confidence in LT3001's broad applicability.”

— Thomas Devlin, MD, PhD, FSVIN, Director of the CHI Memorial Neuroscience Institute, Professor of Neurology Morehouse School of Medicine and principal investigator of the LT3001-205 study

“While many drugs frequently succeed in preclinical, animal-based studies, they fail to show safety or efficacy in human trials. Our efficacy data with LT3001, spanning diverse patient populations, is exciting and provides direction for our phase 3 programs.”

— Sheng-Wen Yeh (Mimi) Ph.D., General manager, Lumosa

What’s next

Based on feedback from the U.S. Food and Drug Administration, Lumosa aims to accelerate global Phase 3 development of LT3001 and deliver innovative and effective treatment options for stroke patients worldwide.

The takeaway

LT3001's dual mechanism of enhancing the body's natural clot-dissolving processes while protecting brain tissue from oxidative damage offers a promising new therapeutic pathway for acute ischemic stroke patients who are ineligible for or unable to benefit from current standard reperfusion treatments, potentially restoring independence to thousands of patients annually.